Researchers looked at the health records of more than 841,000 women with stage I to III breast cancer at 68 US health care organizations. They compared the outcomes of people who used GLP-1 drugs versus those who did not, as well as the outcomes of people who were taking other diabetes medications, such as insulin, metformin or SGLT2 inhibitors.
